Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory and Relapsed Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01794520
What this trial is testing

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 117
Early research (Phase 1)UnknownNCT05271682
What this trial is testing

A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. 40
Not applicableNot Yet RecruitingNCT07376720
What this trial is testing

A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment

Who this might be right for
Multiple Myeloma
Donghua Zhang 28
Early research (Phase 1)Study completedNCT01727778
What this trial is testing

Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Drug Safety
Patrys Ltd. 12
Not applicableLooking for participantsNCT06279026
What this trial is testing

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 15
Testing effectiveness (Phase 2)Looking for participantsNCT06119685
What this trial is testing

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Who this might be right for
NHLMultiple MyelomaBlood Cancer+4 more
Indapta Therapeutics, INC. 128
Early research (Phase 1)Study completedNCT00015925
What this trial is testing

MS-275 in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Early research (Phase 1)Study completedNCT05139225
What this trial is testing

TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)UnknownNCT03940833
What this trial is testing

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Who this might be right for
Multiple Myeloma
Asclepius Technology Company Group (Suzhou) Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06669247
What this trial is testing

Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals 186
Not applicableLooking for participantsNCT06515262
What this trial is testing

Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 10
Testing effectiveness (Phase 2)UnknownNCT04714827
What this trial is testing

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanxi Province Cancer Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT06971380
What this trial is testing

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

Who this might be right for
Multiple Myeloma, Refractory to Standard TreatmentMultiple Myeloma, RelapsedLight Chain Amyloidosis
Polina Stepensky 180
Early research (Phase 1)Study completedNCT01118689
What this trial is testing

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple MyelomaWaldenstrom Macroglobulinemia
Millennium Pharmaceuticals, Inc. 39
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Testing effectiveness (Phase 2)Study completedNCT06055075
What this trial is testing

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche 19
Testing effectiveness (Phase 2)Ended earlyNCT01062230
What this trial is testing

Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Arkansas 6
Testing effectiveness (Phase 2)Study completedNCT01034553
What this trial is testing

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Mayo Clinic 26
Testing effectiveness (Phase 2)Looking for participantsNCT06822972
What this trial is testing

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University 27
Next Page